The randomized multicenter ATLAS trial of more than 500 persons has found that subcutaneous implantable cardioverter defibrillators (S-ICDs) reduce perioperative, lead-related complications without significantly compromising the effectiveness of ICD shocks, but with more early postoperative pain and a trend for more inappropriate shocks. The study is published in Annals of Internal Medicine.